Rakuten Aspyrian Raises $150 Million in Series C Financing
SAN DIEGO, Aug. 23, 2018 /PRNewswire-AsiaNet/ -- -- Funds will support pivotal Phase 3 trial of ASP-1929 in head and neck cancer and additional pipeline expansion to treat other tumor types Rakuten Aspyrian, a biotechnology company developing precision-targeted cancer therapies based on its ...
Read more https://view-release/?pr-id=74878